Labcorp Holdings Inc.

Labcorp Holdings Inc. is an American clinical laboratory and drug development services company that processed more than 750 million tests for patients across approximately 100 countries in fiscal 2025, generating $13.95 billion in revenue. Through its two segments — Diagnostics Laboratories (Dx), the largest clinical lab network in the United States, and Biopharma Laboratory Services (BLS), a central-lab and early-development partner to the pharmaceutical industry — Labcorp sits at the intersection of U.S. healthcare utilization and global drug development spending, supporting more than 85% of FDA-approved drugs.

This is a story about an incumbent industrial franchise executing a deliberate shift from a commodity testing provider into a specialty-driven, technology-enabled healthcare platform. The Fortrea spin-off in mid-2023 sharpened the focus; the question since has been whether the remaining business can generate enough organic growth and margin expansion to earn the multiple the market now assigns it. The file turns on whether Labcorp's twin engines — specialty diagnostics and central-lab services — can outrun the structural reimbursement headwinds that have defined the clinical lab industry for a decade.